PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

Inclusion Criteria 1. Subject has given written informed consent 2. Male or female, at least 18 years of age 3. Diagnosis and treatment of HF (regardless of LVEF) for ≥ 3 months and NYHA Class II HF (NYHA II Cohort) or NYHA III (NYHA III Cohort) at time of Screening

4. Subjects should be receiving appropriate medical therapy for heart failure accordingto current AHA/ACC guidelines as standard-of-care for HF therapy in the UnitedStates, or current ESC guidelines for HF treatment in Europe for at least 30 daysprior to the Screening/Enrollment visit. Stable is defined as no more than a 100%increase or 50% decrease in dose. These criteria may be waived if a subject isintolerant of ACE-I, ARB, ARNI), MRA, beta-blockers, or SGLT2i, subject is unable toafford these agents, subject has contraindications to these agents, or these agentsare not indicated under the Guidelines. Such intolerance, lack of affordability,contraindications, or lack of indications must be documented.

5. HFrEF (EF < 50%): Subject has been on stable medications maximized to the subject'stolerance of ACE-I or ARB or ARNI, MRA, beta-blockers, and SGLT2i as determined bythe study investigator for at least 30 days prior to Screening/Enrollment

6. HFpEF (EF ≥ 50%): Subject has been on stable medication maximized to the subject'stolerance of SGLT2i as determined by the study investigator for at least 30 daysprior to Screening/Enrollment 5. NYHA II Cohort- HF related hospitalization within 6months (last hospitalization should be 30 days before Screening /Enrollment) 5. NYHAIII Cohort -HF related hospitalization within 12 month (last hospitalization shouldbe 30 days before Screening/Enrollment)

7. Subjects should be on diuretic therapy (≥40 mg] furosemide or equivalent) for ≥ 1 month at time of Screening

8. Subjects who are physically able to hold the myCordella™ Patient Reader unit (approximate weight 1.3lb) against the ventral thoracic surface for up to 2minutes per day while in a seated position, as well as dock and undock themyCordella™ Patient Reader

9. Subjects with sufficient eyesight, hearing, and mental capacity to respond tothe myCordella™ Patient Reader's audio/visual cues and operate the myCordella™Patient Reader

10. Subject has sufficient Cellular and/ or Wi- Fi Internet coverage at home

11. Subject agrees to return to the treating Investigator for all scheduled followup visits and can return to the hospital for follow up

Exclusion Criteria:

1. ACC/AHA Stage D refractory HF (including a known history of >24 hours of IVinotropic therapy to support circulation within the past 6 months (other thanrelation to a procedure))

2. Subjects with history of recurrent pulmonary embolism (≥2 episodes within 5years prior to Screening Visit) and/or deep vein thrombosis in the femoral orIJ vein used for access (< 3 month prior to Screening Visit)

3. Subjects with a resting systolic blood pressure <90 mmHg and/ or severepre-capillary pulmonary hypertension with a pulmonary artery systolic pressureof ≥70 mm/Hg with pulmonary capillary wedge pressure ≤ 15 mmHg at the CordellaPA Sensor Implant RHC (V2)

4. Subjects who have had a major cardiovascular (CV) event (e.g., myocardialinfarction, stroke) within 3 months of the Screening Visit

5. Unrepaired severe valvular disease

6. Subjects with significant congenital heart disease that has not been repairedand would prevent implantation of the Cordella PA Sensor or mechanical/tissueright heart valve(s)

7. Subjects with known coagulation disorders

8. Subjects with a hypersensitivity or allergy to platelet aggregation inhibitorsincluding aspirin, clopidogrel, prasugrel, and ticagrelor; or patients unableto take dual antiplatelet or anticoagulants for one-month post implant

9. Known history of life-threatening allergy to contrast dye.

10. Subjects whereby RHC is contraindicated

11. Subjects with an active infection at the Cordella Sensor Implant Visit

12. Subjects with a GFR <20 ml/min or who are on chronic renal dialysis

13. Implanted with Cardiac Resynchronization Therapy-Pacemaker (CRT-P) or CardiacResynchronization Therapy-Defibrillator (CRT-D), or having undergonemitral/tricuspid valve repair/replacement within 90 days or catheter ablationfor atrial fibrillation within 30 days prior to screening visit

14. Received or are likely to receive an advanced therapy (e.g., durable mechanicalcirculatory support or lung or heart transplant) in the next 24 months

15. Subjects who are pregnant or breastfeeding

16. Subjects who are unwilling or deemed by the Investigator to be unwilling tocomply with the study protocol, or subjects with a history of non-compliance

17. Severe illness, other than heart disease, which would limit survival to <2years

18. Subjects whose clinical condition, in the opinion of the Investigator, makesthem an unsuitable candidate for the study

19. Subjects enrolled in another investigational trial with an active Treatment Arm

20. Subject who is in custody by order of an authority or a court of law